International Journal of Hyperthermia最新文献

{"title":"Comparison of thermal ablation and surgery for hyperparathyroidism: a meta-analysis.","authors":"Huan-Yu Cui, Xiu-Mei Bai, Hong Yang, Yun He","doi":"10.1080/02656736.2024.2441402","DOIUrl":"https://doi.org/10.1080/02656736.2024.2441402","url":null,"abstract":"<p><strong>Objective: </strong>Surgery and thermal ablation are both viable treatment modalities for patients diagnosed with hyperparathyroidism (HPT). However, the comparative efficacy of these approaches remains uncertain. The objective of this meta-analysis is to evaluate the effectiveness of surgical complications and therapeutic strategies in managing HPT.</p><p><strong>Methods: </strong>The databases PubMed, EMBASE, the Cochrane Library, the Web of Science, CNKI and Wan Fang were systematically searched from inception to December 12, 2023 to identify relevant studies comparing thermal ablation with surgical parathyroid hormone therapy. Data analysis was conducted using Review Manager Version 5.4.</p><p><strong>Result: </strong>A total of 15 studies were incorporated into the meta-analysis, comprising 1,115 participants drawn from 12 cohort studies and three randomized controlled trials. The results indicated no significant difference in parathyroid hormone levels between the two treatment options (mean difference: 29.25, 95% CI: -4.99-63.69, <i>p</i> = 0.09), calcium (MD: 0.00, 95%CI: 0.07-0.08, <i>p</i> = 0.94), phosphorus (MD: -0.05, 95% CI: -0.13-0.04, <i>p</i> = 0.28) and the risk of persistence and/or recurrence (OR: 1.01, 95% CI: 0.63-1.62, <i>p</i> = 0.97). The probability of hoarseness (OR: 0.57, 95% CI: 0.35-0.93, <i>p</i> = 0.02) and hypocalcemia (OR: -0.12, 95% CI: -0.19- -0.05, <i>p</i> < 0.01) was lower after thermal ablation than with surgery. Comparable results were observed in instances of secondary and primary hyperparathyroidism.</p><p><strong>Conclusion: </strong>It can be concluded that surgery and thermal ablation are effective modalities for treating hyperparathyroidism. Thermal ablation has been shown to reduce the likelihood of hoarseness and hypocalcemia. Further validation of these results necessitates conducting comprehensive multicenter randomized controlled trials.</p>","PeriodicalId":14137,"journal":{"name":"International Journal of Hyperthermia","volume":"42 1","pages":"2441402"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Hashimoto's thyroiditis on radiofrequency ablation for papillary thyroid micro-carcinoma: a cohort study of 391 patients.","authors":"Limei Lai, Chun Zhou, Zhenhua Liu, Jingwen Zhang, Xiaofeng Ni, Juan Liu, Ning Li, Shujun Xia, Yijie Dong, Jianqiao Zhou","doi":"10.1080/02656736.2024.2426607","DOIUrl":"https://doi.org/10.1080/02656736.2024.2426607","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the impact of Hashimoto's thyroiditis (HT) on radiofrequency ablation (RFA) outcomes for papillary thyroid microcarcinoma (PTMC).</p><p><strong>Methods: </strong>A retrospective study of 391 PTMC patients treated with RFA from March 2017 to August 2020, divided by HT accompanied or not. Ablation area size, volume reduction ratio (VRR), lesion disappearance, complications, and recurrences were analyzed.</p><p><strong>Results: </strong>391 patients (mean age, 41.3 ± 11.2 [SD]; 317 women, 110 with HT) were evaluated. The follow-up time was 2 years. HT+ PTMC patients (Group A) exhibited larger ablation diameters at 1st and 3rd month post-RFA. In comparison, PTMC patients (Group B) had larger diameters at 1st and 3rd months but smaller at 6th months, returning to baseline around 6th month in Group B and 9th month in Group A. VRRs in Group B were greater than Group A at 3rd, 6th, 9th, 12th and 15th month, all <i>p</i> < 0.05). The <i>Kaplan-Meier</i> curves revealed a slower lesion disappearance rate in A (12th) compared to B group (9th). Complication and recurrence rates were similar for both groups (4.4% and 0.8% overall, Group B vs Group A: 4.3% vs 4.6%, <i>p</i> = 0.905; 0.4% vs 1.8%, <i>p</i> = 0.192).</p><p><strong>Conclusion: </strong>HT delays the resorption of PTMC lesions following RFA, but it does not impact the procedure's effectiveness or safety. Regardless of HT status, RFA remains a viable alternative to surgery for PTMC.</p>","PeriodicalId":14137,"journal":{"name":"International Journal of Hyperthermia","volume":"42 1","pages":"2426607"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nomogram for predicting the efficacy of high-intensity focused ultrasound ablation for uterine fibroids based on oxytocin experimentation and ultrasonographic features: a retrospective single-center study.","authors":"Sheng Chen, Danling Zhang, Guisheng Ding, Mengqi Chen, Songsong Wu, Jianzhong Zou","doi":"10.1080/02656736.2024.2436602","DOIUrl":"https://doi.org/10.1080/02656736.2024.2436602","url":null,"abstract":"<p><strong>Objective: </strong>To develop and validate a nomogram for predicting the effectiveness of high-intensity focused ultrasound (HIFU) ablation for uterine fibroids based on oxytocin experiments combined with sonographic features.</p><p><strong>Methods: </strong>Sixty patients with uterine fibroids treated with HIFU combined with oxytocin for uterine fibroids were retrospectively analyzed. Before HIFU treatment, all patients underwent abdominal ultrasonography and oxytocin testing for classification. Predictive factors were selected through univariate and multivariate logistic regression analyses. A predictive model for the clinical efficacy of HIFU treatment of uterine fibroids was established using the R language. The model was visualized by a nomogram, and its discriminative ability, calibration, and clinical value were evaluated.</p><p><strong>Results: </strong>Types of myomas, classification of blood flow around the myomas, location of the myomas, and classification of oxytocin were selected as the final predictive factors to construct the model. The calibration curve of the nomogram demonstrated good consistency between actual observations and nomogram predictions, with an absolute error of 0.066. The model's discriminative ability was evaluated by the area under the curve, which was 0.887 (95% CI: 0.818-0.955). The sensitivity and specificity were 84.4% and 78.8%, respectively, indicating that the model had a good predictive value for the ablation situation. Decision curve analysis showed that the model had high clinical applicability, with the maximum net benefit threshold probability interval ranging from 12.0% to 80.5%.</p><p><strong>Conclusion: </strong>The prediction model for HIFU treatment of uterine fibroids, based on ultrasound characteristics and oxytocin test, shows strong predictive ability and may help clinicians choose suitable patients for treatment.</p>","PeriodicalId":14137,"journal":{"name":"International Journal of Hyperthermia","volume":"42 1","pages":"2436602"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of first-line radiofrequency ablation combined with systemic chemotherapy plus targeted therapy for initially unresectable colorectal liver metastases.","authors":"Yaqing Kong, Xiaoyu Huang, Gang Peng, Xiaojing Cao, Xiang Zhou","doi":"10.1080/02656736.2024.2432988","DOIUrl":"https://doi.org/10.1080/02656736.2024.2432988","url":null,"abstract":"<p><strong>Background/objective: </strong>The optimal strategy for patients with colorectal liver metastases is still controversially discussed. This study aimed to evaluate the efficacy of radiofrequency ablation (RFA) combined with systemic chemotherapy plus targeted therapy as first-line treatment in patients with initially unresectable colorectal liver metastases (CRLM), to identify prognostic factors and construct nomograms predicting survival.</p><p><strong>Methods: </strong>This retrospective study included patients with initially unresectable CRLM treated with (study group <i>n</i> = 74) or without (control group <i>n</i> = 83) RFA at the National Cancer Center from January 2018 to January 2021. Survival curves were assessed using the Kaplan-Meier method and log-rank test. Univariate and multivariate Cox regression analyses were used to determine prognostic factors and include these factors in the nomograms to predict progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>The study group had significantly better median PFS (17.16 months vs. 8.35 months, <i>p</i> < 0.01) and OS (34.9 months vs. 21.1 months, <i>p</i> < 0.01) than the control group after propensity score matching. Cox regression analyses identified RFA treatment and clinical risk score (CRS) as independent prognostic factors for PFS. The largest diameter of liver metastases, RFA treatment, and CRS were independent prognostic factors for OS. Based on this finding, nomograms with good discrimination and calibration were constructed.</p><p><strong>Conclusion: </strong>RFA combined with systemic chemotherapy plus targeted therapy as first-line treatment could significantly prolong PFS and OS in patients with initially unresectable CRLM compared with systemic chemotherapy plus targeted therapy. The nomograms predicting PFS and OS might help clinicians select personalized treatment.</p>","PeriodicalId":14137,"journal":{"name":"International Journal of Hyperthermia","volume":"42 1","pages":"2432988"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of RAS, BRAF mutations and microsatellite status in peritoneal metastases from colorectal cancer treated with cytoreduction + HIPEC: scoping review.","authors":"Valentina Zucchini, Fabrizio D'Acapito, Ilario Giovanni Rapposelli, Massimo Framarini, Daniela Di Pietrantonio, Riccardo Turrini, Eleonora Pozzi, Giorgio Ercolani","doi":"10.1080/02656736.2025.2479527","DOIUrl":"https://doi.org/10.1080/02656736.2025.2479527","url":null,"abstract":"<p><strong>Background: </strong>Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown survival benefits in select patients with peritoneal metastases (PM) from colorectal cancer (CRC). Molecular alterations, particularly RAS/BRAF mutations and Microsatellite Instability (MSI), play crucial roles in prognostic stratification and treatment planning, influencing both disease-free survival (DFS) and overall survival (OS). This scoping review evaluates the prognostic role of MSI and RAS/BRAF mutations in patients with PM-CRC treated with CRS-HIPEC.</p><p><strong>Design: </strong>A literature search was conducted across several databases to identify papers published between 2000 and September 2024. We selected 18 publications that considered DFS and OS as primary or secondary outcomes in patients with RAS/BRAF mutations and MSI following CRS-HIPEC treatment. Studies involving appendiceal cancer, peritoneal disease from non-CRC, pediatric patients, or subjects not treated with CRS-HIPEC were excluded.</p><p><strong>Results: </strong>Most studies suggest that RAS and BRAF mutations have a negative influence on survival outcomes. While inconsistencies exist, RAS mutations are generally associated with worse DFS. Specific KRAS subtypes such as KRASMUT2 or KRAS G12V and the BRAF V600 variant correlate with poorer prognosis. MSI status appears to attenuate the adverse effects of RAS/BRAF mutations on survival, although conflicting data persist.</p><p><strong>Conclusion: </strong>RAS and BRAF mutations correlate with poorer outcomes in PM-CRC, underscoring the need for mutation-informed strategies to refine HIPEC and systemic therapies. Recognizing subtypes may improve patient selection for CRS-HIPEC, optimizing both local disease control and long-term survival. Future research should incorporate these molecular profiles to enhance therapeutic decision-making and better address this challenging condition.</p>","PeriodicalId":14137,"journal":{"name":"International Journal of Hyperthermia","volume":"42 1","pages":"2479527"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cesarean section diverticulum area predicting the intraoperative hemorrhage at suction curettage for cesarean scar pregnancy after focused ultrasound ablation surgery.","authors":"Jun-Rong Huang, Li-Ya Sun, Ying Tang, Ming-Bo Wen, Ming-Tao Yang, Fan Xu, Qiuling Shi, Hui-Quan Hu","doi":"10.1080/02656736.2025.2468757","DOIUrl":"https://doi.org/10.1080/02656736.2025.2468757","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the significance of the cesarean section diverticulum (CSD) area for predicting the intraoperative massive hemorrhage during suction curettage for cesarean scar pregnancy (CSP) after focused ultrasound ablation surgery (FUAS).</p><p><strong>Methods: </strong>Data from 90 patients undergoing suction curettage after FUAS were collected. According to their intraoperative bleeding volume, patients were categorized into three groups: Group 1 (<i>n</i> = 71, <200 mL), Group 2 (<i>n</i> = 9, 200-300 mL) and Group 3 (<i>n</i> = 10, ≥300 mL). Multiple liner regression analysis was performed to identify the influencing factors for CSD area and intraoperative blood loss. The ROC curve was plotted to identify the optimal cutoff values.</p><p><strong>Results: </strong>The median CSD area size in Group 3 (336.8 mm²) was significantly greater than in Groups 1 (128.6 mm²) and 2 (121.6 mm²) (<i>p</i> < .05). Using multiple linear regression analysis, CSD area was associated with intraoperative blood loss (<i>p</i> < .05). The optimal cutoff CSD areas for predicting intraoperative massive hemorrhage volumes ≥ 200 mL and ≥ 300 mL were 202.05 mm² and 241.90 mm², respectively. The mean gestational sac diameter and preoperative symptoms (+) were positively related to CSD area, while residual myometrial thickness was negatively correlated with the CSD area. CSD area showed the greatest relationship to sonication time (r_s = 0.42), treatment time (r_s = 0.316) and total energy used for ablation (r_s = 0.415).</p><p><strong>Conclusion: </strong>The preoperative CSD area could predict intraoperative massive hemorrhage during suction curettage after FUAS, which might inform therapy strategies for CSP patients.</p>","PeriodicalId":14137,"journal":{"name":"International Journal of Hyperthermia","volume":"42 1","pages":"2468757"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143500885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiofrequency ablation with or without conventional transarterial chemoembolization for subcapsular versus nonsubcapsular hepatocellular carcinoma within Milan criteria: a propensity score-matched study.","authors":"Haitao Guan, Yong Xie, Tianshi Lyu, Li Song, Xiaoqiang Tong, Jian Wang, Yinghua Zou","doi":"10.1080/02656736.2025.2452930","DOIUrl":"https://doi.org/10.1080/02656736.2025.2452930","url":null,"abstract":"<p><strong>Objective: </strong>Our study was to compare the therapeutic outcomes of radiofrequency ablation (RFA) with or without conventional transarterial chemoembolization (cTACE) for hepatocellular carcinoma (HCC) within Milan criteria in subcapsular versus nonsubcapsular locations by using propensity score matching.</p><p><strong>Materials and methods: </strong>This retrospective study included 171 consecutive HCC patients meeting Milan criteria who initially received RFA with or without cTACE at a tertiary academic center between January 2017 to December 2022. Technical success rate, progression-free survival (PFS) were recorded. Factors predicting PFS after RFA with or without cTACE were investigated through a Cox proportional hazard model.</p><p><strong>Results: </strong>The cumulative 1-, 3-, and 5-year PFS were 73.9%%, 27.7%%, and 7.7%, respectively. The cumulative PFS rates were 76.1% and 17.3% at 1 and 3 years, respectively, in the subcapsular group and 71.8% and 37.2% in the nonsubcapsular group (<i>p</i> = 0.034). Matching yielded 49 matched pairs of patients. In the matched group, corresponding cumulative PFS rates were 75.6% and 14.6% at 1 and 3 years, respectively, in the subcapsular group and 69.6% and 30.2% in the nonsubcapsular group (<i>p</i> = 0.156). Multivariate analysis confirmed that subcapsular tumor location was not an independent risk factor for PFS. Additionally, differences in technical success rate were not significant between groups.</p><p><strong>Conclusion: </strong>The differences in PFS rates and technical success rate in HCC patients within the Milan criteria who received RFA with or without cTACE were not significant between the subcapsular and non-subcapsular groups. Future larger prospective multicenter trials are needed to validate these findings.</p>","PeriodicalId":14137,"journal":{"name":"International Journal of Hyperthermia","volume":"42 1","pages":"2452930"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of HSPA14 in breast cancer: implications for tumorigenesis, immune response modulation, and personalized therapies.","authors":"Ruipeng Zhao, Xiaocun Zhu, Wan Wei, Linlin Zhen","doi":"10.1080/02656736.2025.2452922","DOIUrl":"https://doi.org/10.1080/02656736.2025.2452922","url":null,"abstract":"<p><strong>Background: </strong>Heat shock proteins have been implicated in the process of carcinogenesis. HSPA14, a member of the heat shock protein family, remains poorly understood in terms of its significance and pathomechanisms in breast cancer.</p><p><strong>Methods: </strong>We analyzed the expression levels of HSPA14 and its prognostic significance in breast cancer using TCGA data. TCGA data was used to investigate the association between HSPA14 expression and clinicopathological features in breast cancer patients. GSEA analysis was conducted to identify the biological function of HSPA14. Spearman's correlation analysis was performed to examine the correlation between HSPA14 expression and immune cell infiltration, as well as immune checkpoint genes. Single cell transcriptomic data from GSE114727 was utilized to calculate the expression of HSPA14 in different cell subpopulations. The data on HSPA14 levels and drug sensitivity were extracted from the CellMiner dataset. The mRNA expression of HSPA14 was validated through cell experiments.</p><p><strong>Results: </strong>HSPA14 expression is elevated in breast cancer, which is associated with poor overall survival. It can serve as a diagnostic biomarker for breast cancer patients. Pathway analysis revealed that HSPA14-associated differential genes are involved in cell cycle, apoptosis, cellular response to heat stress, and more. Additionally, HSPA14 expression is significantly correlated with the immune microenvironment. The expression of HSPA14 may also indicate drug sensitivity.</p><p><strong>Conclusion: </strong>Our study elucidates the involvement of HSPA14 in tumorigenesis, particularly in modulating the immune response, shaping the immune microenvironment, and contributing to drug resistance, which are pivotal for the development of personalized breast cancer therapies.</p>","PeriodicalId":14137,"journal":{"name":"International Journal of Hyperthermia","volume":"42 1","pages":"2452922"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An automated software algorithm for optimizing microwave ablation parameters for treatment of liver tumors.","authors":"Sabrina Q R Liew, Nathaniel Rex, Celina Hsieh, Hyeonseon Kim, Scott A Collins, Grayson L Baird, DaeHee Kim, Aaron W P Maxwell","doi":"10.1080/02656736.2025.2473391","DOIUrl":"https://doi.org/10.1080/02656736.2025.2473391","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the performance of a software algorithm developed to streamline microwave liver ablation parameter selection and to compare performance of this algorithm to that of experienced interventional radiologists.</p><p><strong>Methods: </strong>Patients who underwent microwave ablation for treatment of liver tumors were retrospectively identified. An automated software platform was developed to select the top three 'best fit' combinations of microwave ablation power, time, and vendor for a given tumor to achieve a 5 mm minimal ablative margin (MAM). Generalized linear modeling was used to compare the performance of the software algorithm and experienced interventional radiologists with respect to selected ablation parameters and estimates of total ablative volume (TAV) and MAM. Statistical significance was set at <i>p</i> < 0.05.</p><p><strong>Results: </strong>35 patients were identified who underwent single-antenna microwave ablation for liver tumors. Mean estimated TAV was not significantly different between clinical practice (24.96 cm³, 95% CI: 21.18 - 28.75 cm³) and algorithm-derived parameters (23.89 cm³, 95% CI: 20.04 - 27.74 cm³; <i>p</i> > 0.05), indicating agreement in overall treatment approach. However, the algorithm consistently generated ablation parameter combinations with more favorable estimated MAM metrics and significantly lower variability (first algorithm: -5.33 mm, 95% CI -5.40 - -5.26 mm; second algorithm: -5.83 mm, 95% CI -6.01 - -5.65 mm; third algorithm: -6.06 mm, 95% CI -6.30 - -5.83 mm) compared to interventional radiologists (-1.02 mm, 95% CI -2.02 - -0.03 mm).</p><p><strong>Conclusion: </strong>Streamlining microwave liver ablation parameter selection using an automated software algorithm reduces variability and improves estimated MAM coverage of liver tumors.</p>","PeriodicalId":14137,"journal":{"name":"International Journal of Hyperthermia","volume":"42 1","pages":"2473391"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of US-guided thermal ablation and surgery for papillary thyroid cancer: a systematic review and meta-analysis.","authors":"Na Yu, Zhen-Long Zhao, Ying Wei, Shi-Liang Cao, Jie Wu, Ming-An Yu","doi":"10.1080/02656736.2025.2464206","DOIUrl":"https://doi.org/10.1080/02656736.2025.2464206","url":null,"abstract":"<p><strong>Objective: </strong>We conducted the systematic review and meta-analysis to comprehensively compare ablation and surgery in terms of effectiveness, safety and multiple factors affecting life quality of patients with papillary thyroid cancer (PTC).</p><p><strong>Methods: </strong>PubMed, Embase, Scopus, Web of Science and EBSCO were searched for relevant studies published between January 1980 and September 2023. Two reviewers independently extracted data according to the PRISMA recommendations and assessed the quality of each study with the Cochrane Risk of Bias Tool. Pooled analyses were performed using random or fixed-effects models, as appropriate.</p><p><strong>Results: </strong>A total of 4829 patients with PTC from 19 eligible studies were included. Through the meta-analysis, similar tumor progression (OR: 1.07; 95% CI 0.78, 1.48; <i>p</i> = 0.66) and recurrence-free survival (OR: 0.86; 95% CI, 0.55, 1.34; <i>p</i> = 0.50) were found between the patients undergoing ablation and those undergoing surgery. More strikingly, the lower risk of major complications (OR: 0.31; 95% CI 0.24, 0.41; <i>p</i> < 0.001), the shorter hospital stay (MD = 3.67 d; 95% CI, -4.89, -2.44; <i>p</i> < 0.001), the abbreviated procedure time (MD: -66.33 min, 95% CI, -77.08, -55.59; <i>p</i> < 0.001), the less intraoperative blood loss (MD: -27.43 ml, 95% CI, -34.60, -20.27; <i>p</i> < 0.001) and the lower treatment cost (MD: -860.42 USD, 95% CI, -1008.03, -712.81; <i>p</i> < 0.001) were noticed in ablation techniques compared to surgical operation. Thermal ablation has shown multiple advantages by virtue of its percutaneous puncture compared with surgical resection.</p><p><strong>Conclusion: </strong>As an effective, safe, minimally invasive and economical modality, thermal ablation might be a promising alternative to existing PTC management options.</p>","PeriodicalId":14137,"journal":{"name":"International Journal of Hyperthermia","volume":"42 1","pages":"2464206"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}